SENSEX   77,100.47

+ 109.25

NIFTY   24,056.00

+ 34.35

CRUDEOIL   6,809.00

+ 140.00

GOLD   143,170.00

+ 1,900.00

SILVER   220,600.00

+ 7,525.00

Updated - June 26, 2026 at 11:43 AM.

| Bengaluru

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL.

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Tamiflu Oral Suspension, 6 mg/mL, of Hoffmann-La Roche Inc.

Oseltamivir Phosphate is an influenza neuraminidase inhibitor indicated for the treatment of acute, uncomplicated influenza A and B in patients aged two weeks and older who have been symptomatic for no more than 48 hours. It is also indicated for the prophylaxis of influenza A and B in patients aged one year and older. The company advised referring to the product label for detailed indications.

According to IQVIA, Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, has an estimated market size of US$27 million for the 12 months ended March 2026.

With this approval, Alembic now has a cumulative total of 243 ANDA approvals from the USFDA, comprising 223 final approvals and 20 tentative approvals.

Published on June 26, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.